摘要
目的:评价优妥缓释剂在56例RA患者的安全性和有效性。方法:开放试验,受试者po优妥90mg,疗程3周,对比治疗前和疗程结束时患者关节疼痛、压痛和肿胀、晨僵、握力、血沉和CRP等指标变化,评价其疗效。结果:治疗后所有观察指标均获显著改善(P<0.01或0.05),显著进步和进步率达76.8%。副反应发生率14.3%,无撤药者。结论:优妥为一抗炎止痛作用强、疗效快及副作用小的新药物。
OBJECTIVE:The safety and efficacy of sustained released acemetacin(Rantidil retard)in management of RA were evaluated.METHODS:The study was conducted on 56 patients with RA,and they were treated with oral sustained released acemetacin in a daily dose of 90 mg for a period of 3 weeks.RESULTS:All the parameters observed were improved significantly as compared with base line and a rate of marked improvement and improvement up to 76.8%were obtained.The ADRs incidence was 14.3% .CONCLUSION:Rantidil retard is an effective antiinflammatory drug with a little ADRs.
出处
《中国新药杂志》
CAS
CSCD
1998年第6期459-461,共3页
Chinese Journal of New Drugs